AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 11 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Data from a dendritic cell vaccine study have yielded some unexpected results, scientists report.
Interleukin (IL)-12 diminishes rather than enhances the value of dendritic cells made to express melanoma-expressing antigen (MART-1) in tumor vaccines, according to a study published in Gene Therapy.
Researchers are exploring genetically modified dendritic cells for use as tumor vaccines. In a previous study, Antoni Ribas and colleagues at the University of California - Los Angeles demonstrated the efficacy of using MART-1-transduced dendritic cells to slow or prevent melanoma in murine models.
The vaccine prevented melanoma growth in up to 40% of animals subsequently challenged with cancer cells, according to the investigators.
"Tumors that did develop in immunized mice had slower growth kinetics compared to tumors implanted in naive mice," Ribas and coauthors noted.
Building on data from their original study, the UCLA investigators added IL-12 to the vaccine, transducing dendritic cells with both MART-1 and the cytokine before immunizing study animals.
IL-12 had a negative impact on MART-1 transduced dendritic cells, reducing their effectiveness against melanoma in a dose-wise fashion (Immunosuppressive effects of interleukin-12 ...